Prelude Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2022
Q1 | – | Sell |
-6,890
| Closed | -$183K | – | 1833 |
|
2021
Q4 | $183K | Sell |
6,890
-2,910
| -30% | -$77.3K | ﹤0.01% | 1242 |
|
2021
Q3 | $356K | Hold |
9,800
| – | – | 0.01% | 791 |
|
2021
Q2 | $425K | Buy |
9,800
+1,300
| +15% | +$56.4K | 0.01% | 827 |
|
2021
Q1 | $291K | Hold |
8,500
| – | – | 0.01% | 805 |
|
2020
Q4 | $298K | Hold |
8,500
| – | – | 0.01% | 517 |
|
2020
Q3 | $204K | Buy |
8,500
+2,500
| +42% | +$60K | 0.01% | 499 |
|
2020
Q2 | $110K | Buy |
+6,000
| New | +$110K | 0.01% | 635 |
|
2020
Q1 | – | Sell |
-476
| Closed | -$10K | – | 1448 |
|
2019
Q4 | $10K | Sell |
476
-75
| -14% | -$1.58K | ﹤0.01% | 1241 |
|
2019
Q3 | $10K | Sell |
551
-404
| -42% | -$7.33K | ﹤0.01% | 1017 |
|
2019
Q2 | $25K | Buy |
955
+312
| +49% | +$8.17K | ﹤0.01% | 895 |
|
2019
Q1 | $17K | Sell |
643
-101
| -14% | -$2.67K | ﹤0.01% | 971 |
|
2018
Q4 | $17K | Buy |
744
+56
| +8% | +$1.28K | ﹤0.01% | 944 |
|
2018
Q3 | $22K | Buy |
688
+61
| +10% | +$1.95K | ﹤0.01% | 952 |
|
2018
Q2 | $18K | Buy |
627
+36
| +6% | +$1.03K | ﹤0.01% | 1099 |
|
2018
Q1 | $21K | Buy |
591
+29
| +5% | +$1.03K | ﹤0.01% | 1109 |
|
2017
Q4 | $22K | Buy |
+562
| New | +$22K | ﹤0.01% | 996 |
|
2017
Q3 | – | Sell |
-969
| Closed | -$26K | – | 1726 |
|
2017
Q2 | $26K | Buy |
969
+489
| +102% | +$13.1K | ﹤0.01% | 1091 |
|
2017
Q1 | $16K | Buy |
480
+440
| +1,100% | +$14.7K | ﹤0.01% | 1238 |
|
2016
Q4 | $1K | Sell |
40
-410
| -91% | -$10.3K | ﹤0.01% | 1452 |
|
2016
Q3 | $17K | Sell |
450
-2,450
| -84% | -$92.6K | ﹤0.01% | 1293 |
|
2016
Q2 | $65K | Buy |
2,900
+410
| +16% | +$9.19K | 0.01% | 859 |
|
2016
Q1 | $52K | Buy |
2,490
+420
| +20% | +$8.77K | 0.01% | 894 |
|
2015
Q4 | $63K | Sell |
2,070
-935
| -31% | -$28.5K | 0.01% | 921 |
|
2015
Q3 | $74K | Buy |
3,005
+2,530
| +533% | +$62.3K | 0.01% | 859 |
|
2015
Q2 | $15K | Buy |
+475
| New | +$15K | ﹤0.01% | 1411 |
|